Scribe Therapeutics

Update in progress

SCTX (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing genetic medicines using CRISPR-based tools to address root causes of disease, with emphasis on cardiometabolic conditions in the United States. Programs include STX-1150 for in vivo epigenetic silencing of PCSK9, STX-1200 a CRISPR gene-editing program for elevated Lp(a), and STX-1400 targeting APOC3 mRNA. Uses ELXR for durable silencing and XE for precise editing. Founded 2017, based in Alameda, California.

Company score

Sentiment: 0.48; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.29; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.28; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGM (NGM)
LocationUnited States
CEODr. Benjamin L. Oakes Ph.D.
Founded2017
Employees89
Websitewww.scribetx.com